An EUA for Baricitinib (Olumiant) for COVID-19
Date: December 28, 2020
Issue #:
1614Summary:
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant– Lilly) has been granted an FDA Emergency
Use Authorization (EUA) for treatment of confirmed or
suspected COVID-19 in hospitalized patients ≥2 years
old who require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO); the EUA requires that baricitinib be u sed
in combination with the IV antiviral drug remdesivir(Veklury). Baricitinib has been available for treatment
of rheumatoid arthritis since 2018. Remdesivir was
recently approved by the FDA for treatment of COVID-19
in hospitalized patients ≥12 years old who weigh ≥40
kg; it is available under an EUA for treatment of other
hospitalized patients.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: baricitinib COVID-19 Oluminat remdesivir Veklury Source Type: research
More News: Arthritis | COVID-19 | Drugs & Pharmacology | Emergency Medicine | Rheumatoid Arthritis | Rheumatology